Pfizer, Novartis Learning The VALUE Of Comparative Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis-sponsored trial of Diovan vs. Norvasc finds no difference in cardiac morbidity and mortality. Norvasc shows better blood pressure control and fewer heart attacks, although Novartis is touting Diovan's reduction of diabetes onset. Study is the second comparative trial in recent months in which competitor-sponsored data show an advantage for Pfizer's products.